Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN-005
- Development stage
- Discontinued
- Lead developer
- Genocea Biosciences, Inc.
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GEN-005 is an experimental preclinical immunostimulant and vaccine candidate developed by Genocea Biosciences for the prevention of infectious diseases, specifically malaria. The drug was identified using Genocea's proprietary ATLAS platform, which profiles T-cell responses to identify protective antigens from individuals with natural immunity. In 2014, the program received a $1.2 million grant from the Bill & Melinda Gates Foundation to support the identification of T-cell antigens for a malaria vaccine. Development of GEN-005 was effectively halted following Genocea's strategic shift toward oncology neoantigen vaccines and the company's subsequent liquidation in 2022.
Beyond the preview
Go deeper on GEN-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN-005.